| Title |
Paediatric European Risperidone Studies (PERS): context, rationale, objectives, strategy, and challenges
|
|---|---|
| Published in |
European Child & Adolescent Psychiatry, December 2013
|
| DOI | 10.1007/s00787-013-0498-3 |
| Pubmed ID | |
| Authors |
Jeffrey Glennon, Diane Purper-Ouakil, Mireille Bakker, Alessandro Zuddas, Pieter Hoekstra, Ulrike Schulze, Josefina Castro-Fornieles, Paramala J. Santosh, Celso Arango, Michael Kölch, David Coghill, Itziar Flamarique, Maria J. Penzol, Mandy Wan, Macey Murray, Ian C. K. Wong, Marina Danckaerts, Olivier Bonnot, Bruno Falissard, Gabriele Masi, Jörg M. Fegert, Stefano Vicari, Sara Carucci, Ralf W. Dittmann, Jan K. Buitelaar, The PERS Consortium |
| Abstract |
In children and adolescents with conduct disorder (CD), pharmacotherapy is considered when non-pharmacological interventions do not improve symptoms and functional impairment. Risperidone, a second-generation antipsychotic is increasingly prescribed off-label in this indication, but its efficacy and tolerability is poorly studied in CD, especially in young people with normal intelligence. The Paediatric European Risperidone Studies (PERS) include a series of trials to assess short-term efficacy, tolerability and maintenance effects of risperidone in children and adolescents with CD and normal intelligence as well as long-term tolerability in a 2-year pharmacovigilance. In addition to its core studies, secondary PERS analyses will examine moderators of drug effects. As PERS is a large-scale academic project involving a collaborative network of expert centres from different countries, it is expected that results will lead to strengthen the evidence base for the use of risperidone in CD and improve standards of care. Challenging issues faced by the PERS consortium are described to facilitate future developments in paediatric neuropsychopharmacology. |
Mendeley readers
The data shown below were compiled from readership statistics for 101 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 2% |
| Spain | 1 | <1% |
| United Kingdom | 1 | <1% |
| Unknown | 97 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 18 | 18% |
| Student > Bachelor | 14 | 14% |
| Researcher | 12 | 12% |
| Student > Doctoral Student | 10 | 10% |
| Professor | 6 | 6% |
| Other | 24 | 24% |
| Unknown | 17 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 25 | 25% |
| Psychology | 22 | 22% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 8% |
| Nursing and Health Professions | 5 | 5% |
| Neuroscience | 5 | 5% |
| Other | 12 | 12% |
| Unknown | 24 | 24% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 February 2015.
All research outputs
#20,259,845
of 22,789,566 outputs
Outputs from European Child & Adolescent Psychiatry
#1,483
of 1,641 outputs
Outputs of similar age
#267,745
of 307,887 outputs
Outputs of similar age from European Child & Adolescent Psychiatry
#19
of 21 outputs
Altmetric has tracked 22,789,566 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,641 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 307,887 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.